Highview Capital Management’s Edwards Lifesciences EW Stock Holding History

Highview Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.06M	Buy	22,757 +19,982	+720%	+$1.67M	0.59%	44
2026 Q1	$222K	Hold	2,775	–	–	0.08%	99
2025 Q4	$237K	Hold	2,775	–	–	0.08%	101
2025 Q3	$216K	Hold	2,775	–	–	0.08%	105
2025 Q2	$217K	Sell	2,775 -5,250	-65%	-$392K	0.08%	106
2025 Q1	$582K	Hold	8,025	–	–	0.24%	73
2024 Q4	$594K	Hold	8,025	–	–	0.23%	82
2024 Q3	$530K	Hold	8,025	–	–	0.22%	83
2024 Q2	$741K	Hold	8,025	–	–	0.31%	81
2024 Q1	$767K	Hold	8,025	–	–	0.34%	76
2023 Q4	$612K	Hold	8,025	–	–	0.33%	71
2023 Q3	$556K	Hold	8,025	–	–	0.32%	75
2023 Q2	$757K	Hold	8,025	–	–	0.41%	67
2023 Q1	$664K	Hold	8,025	–	–	0.38%	63
2022 Q4	$599K	Hold	8,025	–	–	0.36%	70
2022 Q3	$663K	Sell	8,025 -264	-3%	-$25.4K	0.49%	54
2022 Q2	$788K	Buy	8,289 +264	+3%	+$27.3K	0.61%	50
2022 Q1	$945K	Hold	8,025	–	–	0.61%	50
2021 Q4	$1.04M	Buy	+8,025	New	+$936K	0.67%	49

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Highview Capital Management's EW Position: Q2 2026 in Review

Highview Capital Management increased its Edwards Lifesciences (EW) stake by 720% in Q2 2026, buying an estimated $1.67M and bringing the position to 22,757 shares worth $2.06M. The position accounts for 0.59% of the portfolio, ranked #44.

Highview Capital Management first reported a position in EW in Q4 2021 and has held it in 19 quarters since. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Highview Capital Management held 22,757 shares of Edwards Lifesciences worth $2.06M as of Q2 2026.
Highview Capital Management bought 19,982 Edwards Lifesciences shares in Q2 2026, an estimated $1.67M.
Edwards Lifesciences made up 0.59% of Highview Capital Management's portfolio in Q2 2026, its #44 holding.
Highview Capital Management first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 19 quarters since.
1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Highview Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.